Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Introduces Reusable Courier Transit Case

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
BioCarrier™ - Designed for local courier routes and multiple site sample collections.

Intelsius has introduced the first of its kind range of solutions, BioCarrier™, specifically designed for local courier routes and multiple site sample collections.

“Intelsius is proudly introducing the BioCarrier line to the life science leaders and industry professionals at the largest and most well attended clinical trial conference of the year,” said David Walsh, CEO, Intelsius. “This is a regulatory compliant solution rather than couriers carrying samples or medicines from clinic to clinic or pharmacy to pharmacy in picnic coolers.”

BioCarrier cases are designed to provide regular route, multiple site sample collection and “home visit” temperature-sensitive injectable drug protection.

The rugged polymer outer with the expanded polypropylene (EPP) insulated liner maintains payload integrity at 2-8 degrees Celsius for 12 hours plus or when using dry ice up to 18 hours.

All three sizes are regulatory compliant with pre-printed UN3373 labels for the shipment of Category B biological samples.

“The rigid, durable, regulatory compliant marked outer cases feature a clasp closure allowing the lid to be secured and the cases to be stacked and locked together, making them an Intelsius exclusive,” said Alex Roskoss, Intelsius European head of technical services.

“These cases were ergonomically designed specifically for couriers to enable safe, comfortable, compliant transportation around the corner or across town,” Roskoss added. Its discreet design keeps the contents confidential.

“Keeping people safe while samples or medicines are being transported around town is the primary reason for creating the BioCarrier line of products,” said Walsh.

Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!